Market capitalization | $18.25m |
Enterprise Value | $22.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.59 |
P/S ratio (TTM) P/S ratio | 0.48 |
P/B ratio (TTM) P/B ratio | 0.69 |
Revenue growth (TTM) Revenue growth | -7.05% |
Revenue (TTM) Revenue | $37.79m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:
1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 38 38 |
7%
7%
|
|
Gross Profit | 26 26 |
7%
7%
|
|
EBITDA | -1.66 -1.66 |
14%
14%
|
EBIT (Operating Income) EBIT | -7.83 -7.83 |
31%
31%
|
Net Profit | -10 -10 |
483%
483%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
Head office | United States |
CEO | A. Kazimi |
Employees | 91 |
Founded | 1999 |
Website | www.cumberlandpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.